ISRCTN54136716已完成未知
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial
aval Hospital Research Center (Canada)0 个研究点目标入组 280 人开始时间: 2005年2月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 280
研究概览
简要总结
- 2010 results in https://www.ncbi.nlm.nih.gov/pubmed/20594555 (added 28/01/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Stable diabetic patients (HbA1c inferior or equal to 9.0%) with previous coronary bypass surgery (1-10 years) and a suitable 40 mm segment in a vein graft and a 20 mm segment in native coronary artery.
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
4 期
Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial TriglycerideDiabetes Mellitus, Type 2NCT00424762University of Texas Southwestern Medical Center150
已完成
4 期
Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular DysfunctionDiabetes Mellitus, Type 2NCT00300911Baskent University45
已完成
2 期
Rosiglitazone to Reverse Metabolic Defects in DiabetesDiabetes Mellitus, Type IIInsulin ResistanceNCT00094796National Heart, Lung, and Blood Institute (NHLBI)70
已完成
不适用
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 DiabetesType 2 DiabetesNCT00549874University of Michigan27
已完成
2 期
The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.Ischemia-Reperfusion InjuryThe Metabolic SyndromeNCT00405015Radboud University Medical Center13